CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use
Most people pick CJC 1295 with DAC because fewer injections sounds like a straightforward win. Same compound, same mechanism, just less hassle. But the injection schedule is not what changes. The underlying hormone pattern is, and that pattern is the whole mechanism.
To understand why that matters, you need the full chain first.
Your pituitary gland releases growth hormone in pulses throughout the day and night, and those pulses are driven by a signaling molecule called GHRH, which stands for growth hormone releasing hormone. GHRH is produced in your hypothalamus, travels down to the pituitary, binds to receptors there, and tells the gland to fire a burst of growth hormone into your blood. That burst does its work, then clears out. Then another pulse comes later. The rhythm looks like a series of sharp peaks with real valleys between them, and that rhythm is not incidental to how growth hormone works. It is how growth hormone works.
CJC 1295 is what is called a GHRH analog, which means it is a molecule designed to mimic GHRH and trigger those same pulses from the pituitary. The version without DAC has a half life of roughly 30 minutes, so it acts fast, stimulates a pulse, and clears before the next natural pulse is due. Your pituitary keeps firing on its own schedule between doses, and the overall pattern stays pulsatile.
DAC stands for drug affinity complex, and it is a modification added to the CJC 1295 molecule that allows it to bind to something called albumin, which is the most abundant protein in your blood and acts as a natural carrier for various compounds. When CJC 1295 binds to albumin, it stops being cleared quickly and instead gets released slowly over time, which is what pushes the half life from 30 minutes up to somewhere between 5.8 and 8.1 days depending on the individual.
That is where the mechanism diverges.
A 2006 study by Ionescu and Frohman looked at what CJC 1295 with DAC actually does to the growth hormone pattern in humans, and the finding was specific. The pituitary still fires pulses. Pulse frequency and magnitude were preserved. But the baseline level of growth hormone between those pulses, what you would call the trough, was elevated 7.5 times above normal. The valleys filled in. What had been a pattern of sharp peaks rising out of a near-zero baseline became a pattern of peaks sitting on top of an already elevated floor, which from the body's perspective looks much more like a continuous elevation than a pulsatile rhythm.
And whether the pattern is pulsatile or continuous turns out to determine whether you actually get the primary benefit most people are using this compound for.
A 2009 study by Surya and colleagues tested exactly this question in humans. They compared pulsatile growth hormone delivery against continuous growth hormone delivery and measured the lipolytic response, which is the rate at which the body breaks down stored fat. The pulsatile group saw lipolysis nearly double from a baseline of 4.1 up to 7.1. The continuous group went from 4.1 to 4.8, which was not statistically different from doing nothing.
The same dose of growth hormone. Completely different outcomes based only on the delivery pattern.
The reason the receptor level explains this goes one layer deeper. When you expose a receptor to its signal continuously, a process called downregulation begins, which is the cell reducing the number or sensitivity of those receptors to protect itself from overstimulation. A 1997 study by Aleppo and colleagues showed that continuous exposure to GHRH for as little as four hours reduced the messenger RNA for GHRH receptors down to 49 to 54 percent of baseline, meaning the pituitary was already pulling back its ability to respond in less than half a day of sustained stimulation. The effect was dose dependent and mediated through a signaling pathway called cAMP. What that means practically is that a long-acting GHRH analog is not just elevating the baseline. It is progressively blunting the very receptors it depends on to produce the response.
The pulsatile pattern avoids this because there is time between pulses for the receptors to reset before the next signal arrives.
This also reframes the comparison between CJC 1295 with DAC and just using growth hormone directly. If you are going to run a continuous elevation of growth hormone, that is precisely what exogenous growth hormone does, and it comes with a known dose, a known half life, and decades of clinical data behind it. CJC 1295 with DAC puts you in a position where you have lost the pulsatile advantage that made a secretagogue the choice in the first place, but you have not gained the precision and predictability of actual growth hormone. It is a middle ground that captures the drawbacks of both approaches without the strengths of either.
The version without DAC preserves the mechanism you actually chose when you chose a secretagogue over direct growth hormone. Short acting, pulse-stimulating, clears fast enough for the body to maintain its own rhythm between doses. If the goal is to amplify what your pituitary already does rather than override it, that is the version that does that.
The irony of the DAC formulation is that it was designed to make the compound more convenient, and convenience is not nothing. But in this case, the modification that makes it last longer is the same modification that shifts it from working with your body's pattern to flattening it. And the pattern is not a side detail. It is the mechanism.
References
- Surya S et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;948:2828-2834 — Pulsatile GH nearly doubled lipolysis 7.1 vs 4.1 baseline, continuous was not significantly different from baseline 4.8 vs 4.1. Source
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;9112:4792-4797 — CJC-1295 DAC preserved pulse frequency and magnitude but elevated basal trough GH 7.5-fold. Source
- Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;913:799-805 — CJC-1295 DAC half-life 5.8-8.1 days due to albumin binding. Source
- Aleppo G et al. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;1383:1058-1065 — Continuous GHRH exposure for 4 hours reduced GHRH receptor mRNA to 49-54% of baseline, dose-dependent and cAMP-mediated. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.